**Original Research**

**Transcriptome and Pathway Analysis Reveals that Adipose-derived Stem Cells Target Inflammatory Factors and Delay the Progression of Diabetic Liver Disease**

Yanli Hou¹,²,³,†, Guoliang Gao¹,²,³,⁴,†, Wenyu Ding¹,²,³, Peishan Wu¹,²,³,⁴, Changqing Liu¹, Dong Lin⁴, Deshan Liu⁵,*, Xiaolei Wang⁶,¹,²,³,†

¹Endocrine and Metabolic Diseases Hospital of Shandong First Medical University, 250062 Jinan, Shandong, China
²Shandong Institute of Endocrine and Metabolic Diseases, 250062 Jinan, Shandong, China
³Jinan Key Laboratory of Translational Medicine on Metabolic Diseases, 250062 Jinan, Shandong, China
⁴Shandong First Medical University, 250018 Jinan, Shandong, China
⁵Department of Traditional Chinese Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 250012 Jinan, Shandong, China
⁶Shandong University of Traditional Chinese Medicine, 250355 Jinan, Shandong, China
*Correspondence: liudeshan@sdu.edu.cn (Deshan Liu); daturawing@163.com (Xiaolei Wang)
†These authors contributed equally.

Abstract

**Background:** Diabetic liver disease is one of the main complications that leads to the aggravation of diabetes, but it has not received sufficient attention. This study aimed to provide a better understanding of the altered molecular networks in diabetic rats with liver damage after stem cell therapy. To a certain extent, our research would be instructive, since almost no studies of this kind have been performed on patients with diabetic liver disease after stem cell therapy. **Methods:** Streptozotocin-induced diabetic rats were treated with adipose-derived stem cells. RNA-Seq analysis was performed on the liver tissues of these animals, and key pathway factors were further identified and validated. **Results:** RNA-Seq analysis revealed numerous affected signaling pathways and functional categories. The results showed that the network of dual specificity phosphatase 1 (*DUSP1*), an oxidative stress-related gene, was prominently activated in the liver after stem cell therapy, and the enrichment of genes associated with liver damage, steatosis and fibrosis was also detected. The extracellular regulated protein kinase (ERK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway may be involved in this process by regulating the nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome. **Conclusions:** These data provide novel insights into liver biology, suggest common alterations in the molecular networks during diabetic liver damage, and show the advantages of stem cell therapy, indicating its further application potential for early treatment of diabetic liver damage and delaying the progression of liver fibrosis in the later stage.

**Keywords:** diabetic liver disease; adipose-derived stem cells; *DUSP1*; ERK; NLRP

1. Introduction

Diabetes mellitus (DM) is one of the most common chronic diseases in the world, and its global prevalence has more than doubled in the past 20 years [1,2]. The traditional complications of diabetes are well known for their prolonged effects and heavy burdens. Complications were once limited to vascular disease, but advances in diagnosis and treatment have brought complications such as cognitive decline, obstructive sleep apnea, and liver disease into view [3]. Recent studies have shown that among individuals with diabetes worldwide, more than half have nonalcoholic fatty liver disease (NAFLD), and nearly half have nonalcoholic steatohepatitis (NASH) [4]. Liver damage or fibrosis, which are major complications of diabetes, can cause serious and irreversible consequences over time, including liver cirrhosis and liver cancer [5], which may also endanger patient lives. Decades of extensive research and clinical trials have resulted in a detailed protocol for the treatment of these diseases, but the specific mechanism remains unclear, greatly limiting early intervention and the prevention and treatment of complications.

Stem cell injection has been widely used to treat hematological diseases, autoimmune diseases and other diseases. Furthermore, based on the current epidemic trend in COVID-19, stem cells have shown great potential in the prevention and treatment of COVID-19 and related sequelae [6–8]. In patients with type 1 diabetes mellitus (T1D)-induced depletion of islet beta cells (β-cells), insulin secretion is completely inadequate, and stem cell transplantation can repair damaged areas. Stem cells can be induced to differentiate into insulin-producing cells (IPCs) and improve the function and proliferation of resident pancreatic islets [9]. Stem cell therapy also has good therapeutic effects on various complications of diabetes, such as protecting against T1D-mediated renal injury and alleviating podocyte...
injury in diabetic kidneys [10]. In a previous study, we demonstrated the therapeutic effect of adipose-derived stem cell (ADSC) injection on diabetes by examining the complications of changes in the liver [11]. We found that stem cells could exert their therapeutic effects by improving mitochondrial permeability transition pore (MPTP) opening, but the specific mechanisms need further examination. In this study, we aimed to further explore the role of mitochondrial function changes in diabetic liver diseases, explore the specific mechanisms and key targets, and provide new ideas for the clinical application of related drugs.

In recent years, transcriptomic analyses of diabetes models have revealed multiple possible targets for, which is consistent with our transcriptome sequencing results. Selnovo germline gain-of-function (GOF) mutations can occur accidentally in the transcriptional regulator signal transducer and activator of transcription 3 (STAT3), which is one of the rarer causes of diabetes. A specific class of CD8+ T cells is inhibited when STAT3 activity is normal, and once this process becomes abnormal, it can lead to the occurrence of diabetes [12]. On the other hand, neurogenin hormone 3 (ngn3) has been shown to be associated with adult β-cell transition, which suggests that this factor may be a potential target for treating DM [13]. Interestingly, recent studies of the transcriptional landscape in human adipocytes from healthy individuals of different sizes and type 2 diabetes mellitus (T2D) patients suggest that excessive mitophagy caused by activation of the mitochondrial reactive oxygen species (ROS) pathway and nuclear factor kappa B (NF-κB) signaling may be associated with T2D with hepatic insulin resistance and hepatic steatosis [14]. In addition, several studies have indicated a possible association between differences in serum fibroblast growth factor 1 (Fgf1) levels and the onset of diabetic cardiomyopathy, which may be a novel use of this target in the field of metabolic disorders [15]. The nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome is the key sensor of cytolytic pathogens or stress signals, and its activity is tightly controlled [16]. After being stimulated, the inflammasome induces the production of active caspase-1 and the subsequent activation of proinflammatory cytokines, including interleukin (IL)-18 and IL-1β. The NLRP3 inflammasome has been implicated in multiple diseases, including diabetes and liver diseases [17]. Our previous study showed that the NLRP3 inflammasome was affected by ADSC treatment [11], but the signaling pathways involved are unclear.

Advances in transcriptome analysis are furthering our understanding of diabetes. In the current study, we compared the RNA-seq results of treated and untreated streptozotocin-induced diabetic rats, analyzed the expression status of each factor and identified multiple potentially significant networks. Our data showed the transcriptomic changes and networks in diabetic rats after ADSC treatment, and we further validated the results using the human hepatoma cell line HepG2 in vitro, setting the foundation for further identification of therapeutic targets for diabetic liver damage.

2. Materials and Methods

2.1 Isolation and Characterization of ADSCs

ADSCs were isolated as described previously [11]. In brief, white adipose tissue from the inguinal region of rats was placed in a digestion solution containing 0.1% collagenase type I and subjected to continuous agitation at 37 °C for 1 h. The reaction was stopped by the addition of culture medium, and the cell suspension was centrifuged at 2000 rpm for 10 min. The acquired cells were resuspended and filtered through 100-µm filters. After being washed twice, the cellular precipitate was resuspended in cell culture medium and cultured in 25 mm² cell flasks at 37 °C in a 5% CO₂ incubator. The cells were cultured in DMEM containing 1 g/L glucose (#11885084, Gibco, Carlsbad, CA, USA), 10% fetal bovine serum (#10099141C, Gibco, Carlsbad, CA, USA) and 1% penicillin/streptomycin at 37 °C in 5% CO₂, and the medium was changed twice per week. The cells were observed daily under an inverted phase contrast microscope. The cells were detached with 0.25% trypsin/0.01% EDTA and replated for passing. We observed that third-generation ADSCs adipogenic and osteogenic differentiation potential, and the immunophenotype of surface markers was examined by flow cytometry. ADSCs of this generation and the following two generations were used in the experiments.

2.2 Animal Experiment

All studies were performed in accordance with the National Institute of Health guidelines and were granted formal approval by the Research Ethics Committee of Shandong Institute of Endocrine & Metabolic Diseases. Male 8-week-old SD rats were exposed to 12 h of light/darkness under constant temperature and humidity and had free access to water and regular food. All of the rats had similar body weights and growth statuses before streptozotocin (STZ) administration. Twenty rats were fasted for 16 h (with free access to water) and were then intraperitoneally injected with 60 mg/kg STZ (#S8050, Solarbio, Beijing, China). After the injection, the rats were allowed to roam free for three days to stabilize the results. Fasting blood glucose levels were taken from the tail tip and measured daily using a glucometer until both blood glucose measurements were above 16.7 mmol/L. At this time, the rats were diagnosed with STZ-induced diabetes, which was set as day 0 of the experiment. Fourteen days later, the rats were randomized again. One group was the ADSC treatment group (ADSC group), and these rats received 2.0 × 10⁶ ADSCs through the tail vein, while the other group was the diabetes group (DM group) and received the same dose of PBS. Body weight and blood glucose levels in the two groups were dynamically monitored weekly. After 6 weeks of ADSC treatment.
or control treatment, the rats were anesthetized after being fasted; blood was collected from the jugular vein, and tissue samples were collected prior to sacrifice.

2.3 RNA-seq Analysis

A TRIzol kit (#15596026, Thermo Fisher Scientific, Waltham, MA, USA) was used to extract total RNA from liver tissue according to the manufacturer’s instructions. The total RNA concentration was determined by a Nanodrop microvolume spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). The ratio of OD260 to OD280 was considered an indicator of RNA purity. In addition, we used agarose gel electrophoresis to ensure RNA integrity and exclude gDNA contamination.

RNA-seq analysis was performed by Health Biotechnology (Shanghai, China). Briefly, the NEBNextTM Ultra II Directional RNA Library Prep Kit was used to construct sequencing libraries for validation and quantification. The Illumina HiSeq X platform was then used for sequencing libraries for validation and quantification. The Illumina HiSeq X platform was then used for sequencing libraries for validation and quantification. The expression level of each gene was estimated by calculating sequences mapped to reference sequences (reads), of which the most commonly used method is read per million transcripts per kilobyte (RPKM). In the DEGseq v1.20.0 software package, the differentially expressed genes (DEGs) were analyzed using the random sampling (MARS) model. Differences in gene expression among samples were considered significant when all of the following conditions were met: fold change (FC) ≥ 2 or < 0.5, false discovery rate (FDR) q value < 0.05 and RPKM ≥ 2 for at least one sample.

2.4 Cell Culture and Treatments

The human hepatoma cell line HepG2 was provided without Mycoplasma contamination and authenticated using short tandem repeat (STR) profiling analysis by Procell Life Science & Technology (Wuhan, China) under the catalog number CL-0103. The cells were maintained in DMEM supplemented with 10% fetal bovine serum and 50 U/mL penicillin/streptomycin in an incubator under a humidified atmosphere of 5% CO₂ and 95% air at 37 °C. We used H₂O₂ treatment to simulate oxidative stress in vitro and observed the effects of ADSC culture supernatant and hepatocyte growth factor (HGF), which is a cytokine secreted by ADSCs, on inflammation and oxidative stress.

HepG2 cells were plated in 6-well plates at 1 × 10⁶ cells/well and grown in medium for 24 h. Then, the cells were pretreated with or without ADSC supernatant, HGF (10 ng/mL), or the extracellular regulated protein kinase (ERK)1/2 inhibitor U0126 (2 µM) for 2 h and were cultured with H₂O₂ (600 µM) for another 6 h to determine the effect of ADSCs on ROS-induced inflammation.

2.5 Western Blotting

To obtain whole protein extracts, rat livers were treated with lysis buffer containing protease and phosphorylation inhibitors. The stained membranes were scanned using the Odyssey CLx imaging system (LI-COR, Lincoln, NE, USA) to measure the fluorescence at 800 nm and 700 nm. The fluorescence intensity of the bands was also quantified with the Odyssey CLx imaging system, and the results are expressed as the fold change relative to the control after normalization to the respective internal control.

Antibodies against P-ERK1/2 (#4370), ERK1/2 (#4695), P-P38 (#4511), P38 (#8690), JNK (#9255), JNK (#9252), P-STAT3 (#9145), STAT3 (#9139), GAPDH (#5174) and β-tubulin (#86298) were obtained from Cell Signaling Technology (CST, Danvers, MA, USA) and used for western blotting.

2.6 Quantitative Reverse Transcription–Polymerase Chain Reaction (qRT–PCR)

Using the QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany), total RNA in each sample was reverse transcribed into cDNA. Using the Light Cycler system, the resultant cDNA was used as a template for real-time quantitative PCR. Nonspecific amplification was used to perform melt curve analysis. The data were normalized to β-actin, which was used as an internal control for normalization. The oligonucleotide primers used in this study are shown in Table 1.

2.7 Gene Enrichment Analysis, Upstream and Downstream Analyses and Interaction Network Modeling

The gene expression data were input into Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems; https://ingenuity.com/) to establish a causal network. Using the QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany), total RNA in each sample was reverse transcribed into cDNA. Using the Light Cycler system, the resultant cDNA was used as a template for real-time quantitative PCR. Nonspecific amplification was used to perform melt curve analysis. The data were normalized to β-actin, which was used as an internal control for normalization. The oligonucleotide primers used in this study are shown in Table 1.

Table 1. Oligonucleotide primers used for quantitative reverse transcription–polymerase chain reaction (qRT–PCR).

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Accession</th>
<th>Forward primer (5’-3’)</th>
<th>Reverse primer (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>myelin basic protein (Mbp)</td>
<td>NM_001052899</td>
<td>CAGCAGCGCTTCTGAAACACC</td>
<td>TGGCTCCCTTCCAAACATCACCT</td>
</tr>
<tr>
<td>lymphocyte antigen 6 complex, locus A-like (Ly6a/l)</td>
<td>NM_001128099</td>
<td>CCATATTTGGCTTCCGCTCCT</td>
<td>CAGGATGACAGAAGACCCACC</td>
</tr>
<tr>
<td>acid phosphatase 3 (AcP)</td>
<td>NM_001134901</td>
<td>CCGAGCAGGCTTACCCCAA</td>
<td>AGAAGCAGACAAATATCCACC</td>
</tr>
<tr>
<td>2′-5′ oligoadenylate synthetase 1F (Oas1f)</td>
<td>NM_001009490</td>
<td>TCACCTCCTGTCGAGACC</td>
<td>TTGGTCCCATCACAAACCC</td>
</tr>
<tr>
<td>amylase 2α3 (Amy2a3)</td>
<td>NM_031502</td>
<td>ATGGACCCACACTGCGGATG</td>
<td>TGCCACCCTCCAAATCCCT</td>
</tr>
<tr>
<td>one cut homeobox 1 (Onecut1)</td>
<td>NM_022671</td>
<td>AATTCAGGCAAATCTGCTCT</td>
<td>CTGGTTCTTCTCTCAGTCTT</td>
</tr>
</tbody>
</table>

The gene expression data were input into Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems; https://ingenuity.com/) to establish a causal network. Using the QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany), total RNA in each sample was reverse transcribed into cDNA. Using the Light Cycler system, the resultant cDNA was used as a template for real-time quantitative PCR. Nonspecific amplification was used to perform melt curve analysis. The data were normalized to β-actin, which was used as an internal control for normalization. The oligonucleotide primers used in this study are shown in Table 1.
Fig. 1. Characteristics of ADSCs and physiological differences between the two groups. (a) Morphology of ADSCs at Passage 3 (×40). (b,c) Differentiation potential of ADSCs into adipocytes and osteoblasts, as shown by Oil Red O and Alizarin Red staining (×100). (d) Surface markers of ADSCs, as shown by flow cytometry. (e) Blood glucose levels in rats were measured weekly. The day on which STZ-induced diabetes was established in rats was referred to as day 0 of the experiment. ADSCs were injected at the end of the second week. (f) OGTT results before the rats were sacrificed and the AUC. DM, Diabetes mellitus; ADSCs, adipose-derived stem cells; STZ, streptozotocin; OGTT, Oral glucose tolerance test; AUC, area under the curve.

2.8 Statistical Analysis

The analyses were performed using Microsoft Excel 2021 and GraphPad Prism 9.0 software (San Diego, CA, USA). The results are reported as the mean ± SD. Comparisons of between groups were performed using unpaired t tests. p < 0.05 was considered significant for the qRT‒PCR and western blot data.

3. Results

3.1 RNA-Seq-Derived Gene Expression Profiles and Related Pathways

Fig. 1a–d shows that ADSCs had adipogenic and osteogenic differentiation potential and were positive for CD29 and CD90 (90.75% and 95.38%) and negative for the leukocyte antigen CD45 (1.49%). These cells met the criteria for ADSCs. The weekly blood glucose levels and the oral glucose tolerance test (OGTT) results before the rats were sacrificed are shown in Fig. 1e,f. There was no significant change in the blood glucose levels between the two groups; however, the area under the curve (AUC) of the OGTT was reduced in the ADSC group compared to the DM group. Moreover, ADSC treatment alleviated hepatic injury in our previous study [11].

To examine the effect of stem cell therapy on the transcriptional landscape, we performed full transcriptome RNA-seq analysis on the liver tissues of those STZ-induced
hyperglycemic rats. Fig. 2a shows liver transcriptome differences in diabetic rats with or without treatment. With $p < 0.05$ and $|\log FC| > 0.5$ as the cutoff criteria, a total of 1770 upregulated transcripts and 362 downregulated transcripts were screened (Fig. 2b). We selected certain highly altered upregulated (Mbp, Ly6al, Acpp) and downregulated (OAas1f, Amy2a3, Onecut1) genes from the RNA-seq data and verified them by qRT-PCR (Fig. 2c). The results were consistent with the RNA sequencing results.

Examining the upregulated gene transcripts into IPA and performing canonical pathway analysis showed that many pathways were activated or inhibited during this process, including the hepatic fibrosis signaling pathway, IL-6 signaling pathway, and insulin receptor signaling pathway, which were significantly enriched (Fig. 2d) and showed the ameliorative effect of stem cell treatment on liver damage, inflammation, and insulin secretion.

3.2 The Effects of ADSCs on Hepatotoxicity-Related Functions

IPA of downstream effectors can be used to predict comprehensive increases or decreases in downstream biological activity and gene-related function based on the causal relationship between measured transcriptome level
changes and these activities and functions. Supplementary Fig. 1a shows a high level of middle and downstream activity and function in the liver tissue of treated and untreated diabetic rats. Fig. 3 shows multiple functional categories that were enriched, such as liver pathological changes and metabolic disorders, which included liver tissue alterations, cell growth and proliferation disorders, and suggested that stem cells could improve liver function and liver injury in DM. Furthermore, functional categories associated with immune system diseases and endocrine system diseases showed significant alterations. Notably, functional categories associated with hepatotoxicity showed significant upregulation, and there were much greater increases than those associated with nephrotoxicity and cardiotoxicity (Fig. 3b and Supplementary Fig. 1b). Liver toxicity was mainly characterized by liver damage, hepatitis, liver steatosis, liver fibrosis (LF) and other factors (Fig. 3c).

Taken together, our data revealed significant decreases in susceptibility to liver damage and DM after stem cell therapy.

3.3 A Chemokine Network Indicating Reduced Liver Damage in Diabetes

Multiple liver-related functional categories were enriched in stem cell-treated diabetic rats compared to untreated diabetic rats. Among the differentially enriched categories, liver damage and liver steatosis were the most prominent (Fig. 3c). Fig. 4a shows a heatmap of the log2 expression values of liver damage-related genes (Ccl4, Abcb1a, Cclb, Cnr2, Ddit3, Hmgb, Isg1, Ii18, Irf3, Mapk14, Nr1i3, Sdc4, Sirt1, Gsk3b, Tgfbr2, S1k24, Klf2, Mboab7 and Cps1) in rat liver tissue. Our previous study showed a strong correlation between TGFB expression and the progression of liver damage [11], which was consistent with the results of this analysis. Overall, the expression of Ccl4, Abcb1a, Cclb, Cnr2, Ddit3, Hmgb, Isg1, Ii18, Irf3, Mapk14, Nr1i3, Sdc4 and Sirt1 in hepatocytes promoted the progression of liver damage in mice, and Gsk3b, Tgfbr2, S1k24, Klf2, Mboab7 and Cps1 expression alleviated liver damage in mice. Interestingly, MAPK14 has previously been shown to alleviate liver damage [18]. This may explain the bidirectional alterations in MAPK14 isoform expression in our data.

Moreover, some genes associated with liver steatosis were downregulated in stem cell-treated diabetic rats compared to untreated diabetic rats (Achd5, Bhlhe40, Casp2, Cnr2, Ddit3, Dnajc7, Egfr, Helz, Ifit2, Ii18, Irf3, Isg15, Isg15, Lime1, Nr1i3, Pipp2, Sirt1, Srf2, Tp53inp1, Thra, Egfr, Epsas1, Foxo1, Gdcl, Gna11, Gpam, Insig2, Insr, Klf2, Lrp6, Mapk14, Mboab7, Mgl1, Acox1, Adipor2, Atf6, S1k24, Pdpk1 and Plin2; Fig. 4b). Interestingly, our data suggest that the progression of liver damage and hepatic lipid accumulation may be ameliorated by the inhibition of Cnr2, Ddit3, Ii18, Irf3, Mapk14, Nr1i3 and Sirt1 following stem cell therapy.

3.4 Upstream Regulator Analysis and Mechanistic Network Analysis Predict that Dual Specificity Phosphatase 1 (DUSP1) Plays an Important Role in the Effects of Stem Cell Treatment on DM

Upstream regulator analysis can predict upstream molecules. Thus, we identified relevant factors by which stem cell therapy inhibits processes related to liver damage. IPA was used to predict possible factors, resulting in 30 factors with a Z score greater than 3 (Table 2). These 30 factors were examined by IPA, and the nine factors shown in Fig. 5a were indirectly associated with liver damage. Among them, DUSP1 plays an important role in the cytosol and mitochondria. Changes in these factors identified by RNA-seq (Fig. 5b,c) were analyzed and showed that IPA predicted the importance of DUSP1 in the effects of stem cell treatment on diabetes.

**Table 2. Upstream regulators predicted by IPA.**

<table>
<thead>
<tr>
<th>Upstream Regulator</th>
<th>Z score</th>
<th>p value of overlap</th>
</tr>
</thead>
<tbody>
<tr>
<td>P38 MAPK</td>
<td>4.355</td>
<td>3.91 x 10^-2</td>
</tr>
<tr>
<td>ZBTB10</td>
<td>4.249</td>
<td>2.73 x 10^-3</td>
</tr>
<tr>
<td>Emdr</td>
<td>4.536</td>
<td>4.90 x 10^-9</td>
</tr>
<tr>
<td>STRA8</td>
<td>3.207</td>
<td>7.42 x 10^-1</td>
</tr>
<tr>
<td>CCND1</td>
<td>3.200</td>
<td>1.02 x 10^-1</td>
</tr>
<tr>
<td>FEV</td>
<td>4.060</td>
<td>3.09 x 10^-4</td>
</tr>
<tr>
<td>SOX2</td>
<td>4.076</td>
<td>7.02 x 10^-5</td>
</tr>
<tr>
<td>REL</td>
<td>3.181</td>
<td>3.02 x 10^-2</td>
</tr>
<tr>
<td>LEF1</td>
<td>3.915</td>
<td>2.06 x 10^-4</td>
</tr>
<tr>
<td>STAT4</td>
<td>4.618</td>
<td>4.69 x 10^-3</td>
</tr>
<tr>
<td>ISL1</td>
<td>3.207</td>
<td>2.68 x 10^-3</td>
</tr>
<tr>
<td>COP5</td>
<td>3.024</td>
<td>1.00 x 10^-2</td>
</tr>
<tr>
<td>INHA4</td>
<td>3.893</td>
<td>2.50 x 10^-3</td>
</tr>
<tr>
<td>CREB1</td>
<td>3.095</td>
<td>9.25 x 10^-4</td>
</tr>
<tr>
<td>PTGER2</td>
<td>3.916</td>
<td>1.15 x 10^-5</td>
</tr>
<tr>
<td>APP</td>
<td>3.091</td>
<td>8.21 x 10^-2</td>
</tr>
<tr>
<td>TICAM1</td>
<td>4.907</td>
<td>3.34 x 10^-2</td>
</tr>
<tr>
<td>MITF</td>
<td>3.703</td>
<td>1.67 x 10^-2</td>
</tr>
<tr>
<td>AHR</td>
<td>3.543</td>
<td>1.76 x 10^-4</td>
</tr>
<tr>
<td>MAPK14</td>
<td>3.731</td>
<td>4.06 x 10^-2</td>
</tr>
<tr>
<td>KMT2D</td>
<td>3.805</td>
<td>7.16 x 10^-4</td>
</tr>
<tr>
<td>NFKB1</td>
<td>3.293</td>
<td>3.07 x 10^-2</td>
</tr>
<tr>
<td>ERBB2</td>
<td>3.802</td>
<td>4.57 x 10^-1</td>
</tr>
<tr>
<td>MEIS1</td>
<td>3.148</td>
<td>4.13 x 10^-2</td>
</tr>
<tr>
<td>TLR3</td>
<td>4.846</td>
<td>4.77 x 10^-2</td>
</tr>
<tr>
<td>CBX5</td>
<td>3.289</td>
<td>2.78 x 10^-2</td>
</tr>
<tr>
<td>DUSP1</td>
<td>3.435</td>
<td>2.42 x 10^-3</td>
</tr>
<tr>
<td>GRIN3A</td>
<td>3.335</td>
<td>3.05 x 10^-4</td>
</tr>
<tr>
<td>CITED2</td>
<td>4.259</td>
<td>4.01 x 10^-2</td>
</tr>
</tbody>
</table>

Upstream regulator analysis of DEGs explained the mechanistic networks underlying the observed changes in gene expression during stem cell therapy for DM (Supplementary Fig. 1), including the STAT4 (Z score = 4.618), PTGER2 (Z score = 3.916), LEF1 (Z score =
Fig. 3. Downstream effector analysis of the two groups. (a) The affected diseases and biological function categories based on the tree map in Supplementary Fig. 1a. (b) The top ten most significantly enriched pathways. (c) The affected hepatotoxicity-related functional categories based on the tree map in Supplementary Fig. 1b. The major colored rectangles indicate a family of associated biological functions or diseases; blue indicates a decrease and orange indicates an increase. The sizes (using Fisher’s exact test p value) of the rectangles indicate whether the category is predicted by IPA to increase or decrease significantly between groups; and higher absolute Z scores are represented by color intensities. NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; ASH, alcoholic steatohepatitis.

3.5 DUSP1 may Affect Liver Function during Stem Cell Treatment of DM

By analyzing the factors that were downstream of DUSP1, the functional networks identified by IPA helped us to identify a mechanistic network in which DUSP1 affects multiple functions through multiple factors. The network is shown as genes and biological relationships between the nodes and lines, and nodes with specific shapes indicate the regulatory effect determined by IPA. The first network we identified consisted of the DEGs, their upstream and downstream relationships, and the functional changes that might result (32; as indicated in the legend); in short, this network probably moderates sensory system development (Fig. 6a). The other interesting enriched network moderated the antiviral response (Fig. 6b). Interestingly, we identified DUSP1 as a key hub gene in liver damage and...
other liver disease networks (Fig. 6c). Furthermore, with the Grow and Path Explorer IPA functions, we confirmed the indirect relationship between \textit{DUSP1} expression and numerous liver diseases (Fig. 6d).

However, we also sought to explore the mechanism by which \textit{DUSP1} causes liver damage. The protein encoded by \textit{DUSP1} can dephosphorylate mitogen-activated protein kinase (MAPK), thus playing an important role in multiple pathological processes. We examined the phosphorylation status of the ERK1/2, P38 and JNK pathways, which are three pathways that play key roles in glucose metabolism disorders, in stem cell-treated diabetic rats compared to untreated diabetic rats. The results showed that the phosphorylation of ERK1/2 was significantly downregulated in ADSC-treated DM rats (Fig. 7a,c). This finding was further confirmed \textit{in vitro}. P-ERK1/2 was increased when HepG2 cells were cultured with \textit{H}_{2}\text{O}_{2}. However, it was restored to some extent when the cells were pretreated with HGF or ADSC supernatant, and there was a similar change in response to the ERK inhibitor U0126 (Fig. 7b,d). Moreover, the change in P-STAT3 was similar to that in P-ERK1/2. P-STAT3 was also reduced when the cells were pretreated with an ERK inhibitor. This result suggested that STAT3 phosphorylation was mediated by the ERK signaling pathway. These results suggested that stem cell therapy could act through \textit{DUSP1}-mediated regulation of the ERK/STAT3 pathway.

Fig. 4. Heatmap showing the amelioration of liver damage and liver steatosis in diabetic rats. Heatmap showing the expression of several upregulated and downregulated genes related to liver damage (a) and liver steatosis (b) in eight diabetic rats treated with or without ADSCs. The data are presented as the log\textsubscript{2} TPM (transcript per million) expression values. The expression values are shown according to the color scale.
4. Discussion

The pathogenesis and pathological processes of diabetes are complex and varied, and organ specificity is obvious, which has not been thoroughly examined thus far [19, 20]. Research on disease-related signaling factors and functional networks by many international research teams has led to the targeted monitoring and treatment of diabetes in clinical practice. Although there have been numerous studies of transcriptional data from diabetic and healthy individuals, few studies have been performed on patients with diabetes after stem cell therapy. Our study investigated the therapeutic effect of ADSC treatment on diabetes-related liver disease, and the results suggested that ADSC treatment may have additional therapeutic effects on diabetes-induced liver injury and identified possible key pathways and important targets in this process.

We performed whole-transcriptome RNA-seq analysis of STZ-induced hyperglycemic rats treated with ADSCs. Furthermore, research into the biology of diabetes has revealed multiple signaling and functional perturbations that occur in response to ADSC therapy during the development of diabetes, showing many important signaling networks in diabetes. Our results revealed the enrichment of genes and pathways according to liver damage, hepatitis, liver steatosis, LF and other hepatic diseases, and changes in the endocrine system and lipid metabolism were also identified. Therefore, we sought to identify relevant factors through which stem cell therapy plays a role in ameliorating liver damage.

Upstream regulator analysis identified DUSP1 as a factor that was significantly downregulated in the transcriptome. At the top of the hierarchy, mechanistic network analyses revealed that DUSP1 activated several signaling pathways: the IL-12 complex, IL-1B, and TNF. Furthermore, silencing DUSP1 in vitro enhanced TNF-α and IL expression in vivo and increased the expression of other proinflammatory factors [21, 22]; in contrast, inhibiting MAPKs and inflammatory gene expression occurring after DUSP1 activation is an important feature of the effects of glucocorticoid [23, 24]. DUSP1 deficiency increases systemic levels of proinflammatory cytokines and can promote inflammatory infiltration, and increased DUSP1 mRNA levels may moderate insulin resistance; this process may be related to TNF [25, 26]. Interestingly, in contrast to the inhibitory effect of DUSP1 on many genes associated with inflammation, DUSP1 silencing positively regulated IL-12p40, an
Fig. 6. Numerous disease-associated enrichment networks in diabetic rats. (a) Schematic of sensory system development and (b) antiviral response functional networks revealed by IPA. In this figure, red indicates activation, while blue indicates suppression. (c,d) DUSP1 is closely related to a variety of liver diseases and lipid metabolism disorders.
Fig. 7. Phosphorylation status of the ERK1/2, P38, JNK and STAT3 pathways. 

(a,c) The phosphorylation of ERK2, P38 and JNK in stem cell-treated diabetic rats and untreated diabetic rats. An unpaired t test was used to compare the two groups. (b,d) The phosphorylation of ERK1/2 and STAT3 in HGF- or stem cell-treated HepG2 cells induced by H_2O_2. An unpaired t test was used to compare the H_2O_2 group with the control (Con) group and the HGF, ADSC or U0126 groups with the H_2O_2 group. ERK, extracellular regulated protein kinase; JNK, c-jun N-terminal kinase; STAT3, signal transducer and activator of transcription 3; HGF, hepatocyte growth factor.

important factor in the activation of the Th1 response, suggesting that DUSP1 modulates Th1 immune responses and plays a role in maintaining antimicrobial defense [27].

Liver damage plays a key role in diabetes [28], which led us to further explore whether DUSP1 was also involved in diabetic liver damage. Our data revealed a change in DUSP1, suggesting that DUSP1 may be an important upstream factor affecting diabetic liver damage. A review of previous studies showed that DUSP1 plays different roles in liver damage caused by different etiologies. Alcohol-induced downregulation of DUSP1 in liver tissue was previously shown to further enhance TNF-α release and promote the progression of liver damage, which may be an important mechanism of alcoholic steatohepatitis (ASH) [29]. In contrast, dexmedetomidine treatment increased glycogen synthase kinase-3 (GSK-3)/DUSP1/nuclear factor erythroid 2-related factor 2 (NRF2) pathway activity, attenuated oxidative stress and apoptosis in the rat liver, and subsequently prevented liver damage [30]. This finding may indicate a complex mechanism of DUSP1 in the involvement of diabetes-induced liver damage.

Mechanistic network analysis showed that the expression of several chemokines (including C-C motif chemokine ligand 4 (CCL4) and C-C motif chemokine ligand 20 (CCL20)) was changed in liver tissue after ADSC treatment compared with untreated diseased tissue. A study showed a potential connection between upregulated CCL4 expression, reduced cholesterol levels in liver tissue and the progression of liver damage, which is consistent with our results [31]. Moreover, massive secretion of CCL20 can activate the p38 MAPK pathway, thereby reducing inflammatory symptoms and improving liver repair in mice [32]. It was also found that inhibiting the chemokine CCL20 reduced immune cell infiltration and extracellular matrix (ECM) production, and ECM production actively promoted NASH progression [33]. In conclusion, altered chemokine expression in liver tissue has multiple consequences, including early liver damage, hepatitis, LF, and even liver cirrhosis.

On the other hand, our results suggest that the activation of another class of proinflammatory mediators, including IL-6, IL-1B, and TNF, has potential inhibitory activity against liver damage. Interestingly, the expression of IL-10, an anti-inflammatory cytokine, was bidirectionally altered in our study, which may indicate a complex mechanism that is active during the treatment of diabetic liver damage. Targeting IL-10 can not only prevent liver damage but also play a role in liver lipid metabolism dysregulation and liver cirrhosis. IL-10, which is preferentially expressed in natural killer cells and can alleviate liver damage to some extent, has been reported to have immunoregulatory effects [34]. Moreover, the receptors for some cytokines were also upregulated, such as Il12rb2. IL-12/IL-23-mediated Th1/Th17 signaling is implicated in the pathogenesis of primary biliary cirrhosis (PBC), and targeting Il12rb2 may alleviate but not reverse the progression of liver damage [35].

In addition to the aforementioned alterations in cytokines and chemokines, we also screened for specific genetic changes, which were to some extent corroborated by previous studies. Several reports have suggested that loss of the protein tyrosine phosphatase 1B (PTP1B) gene inhibits fas expression, which may contribute to resistance to liver damage and lethality [36], as well as to the treatment of lipotoxic liver damage [28]. Significant alterations were also found in MAPK14, an important member of the MAPK family. Despite the dual functions of MAPK14, in most cases, it has been shown that therapeutic targeting of MAPK14 can exert anti-inflammatory and antioxi-
dant effects on the liver by increasing the polarization of M2 macrophages, ultimately facilitating liver regeneration [37,38]. These factors showed a close correlation with DUSP1 in the functional network identified by IPA. Then, we explored the possible signaling pathways regulated by DUSP1. DUSP1 is related to the NLRP3 inflammasome in cerebral injury [39]. It was reported that mesenchymal stem cell-derived exosomes could block the malignant behaviors of hepatocellular carcinoma stem cells through the lncRNA C5orf66-AS1/microRNA-127-3p/DUSP1/ERK axis [40]. In the present study, we found that ADSCs decreased the phosphorylation levels of ERK1/2 and STAT3 in the livers of DM rats and in HepG2 cells induced by H₂O₂ (Fig. 7). These results suggest that the ERK pathway can mediate STAT3 and inflammatory factors involved in ADSC treatment of diabetic liver damage, which might be regulated by DUSP1.

5. Conclusions

In summary, the data in this study suggest that DUSP1 plays an important role in the therapeutic effect of ADSCs on diabetes and that the effects of proinflammatory mediators such as IL-6, IL-1β, TNF and the NLRP3 inflammasome and anti-inflammatory factors such as IL-10 cannot be ignored. Therefore, our data highlight possible targets for ADSCs in diabetes treatment, and determining whether these targets and the related pathways can add to the current arsenal of treatments for diabetes requires further studies with larger sample sizes and clinical experiments.

Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions

XW and DLiu designed the study, acquired funding, reviewed and edited the manuscript. YH and GG performed the research and wrote the manuscript. WD and PW analyzed the data. CL and DLin provided administrative support on the research. CL conducted animal experiments and DLin conducted cell culture and treatments. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work to take public responsibility for appropriate portions of the content and agreed to be accountable for all aspects of the work in ensuring that questions related to its accuracy or integrity.

Ethics Approval and Consent to Participate

The animal study protocol was approved by the Ethics Committee of the Shandong Institute of Endocrine and Metabolic Diseases (2018-008, Oct 2018).

Acknowledgment

Not applicable.

Funding

This work was supported by the China National Natural Science Foundation, grant number 81900736; China Postdoctoral Science Foundation, grant number 2023M732137; Guidelines for Prevention and Intervention of Disability among the Elderly in Shandong Province; Qilu Geriatric Diseases Chinese and Western Academic School Inheritance Workshop Project (No.2022-93-1-10); and Postdoctoral Project of Shandong University of Traditional Chinese Medicine.

Conflict of Interest

The authors declare no conflict of interest.

Supplementary Material

Supplementary material associated with this article can be found, in the online version, at https://doi.org/10.31083/j.fbl2812365.

References


